Highlighting Positive Results in Comparison to Valchlor(R) and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy ...

Highlighting Positive Results in Comparison to Valchlor® and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: ...

A male in his 50s presented with profound leucocytosis, systemic symptoms and marked hepatosplenomegaly. Initial workup with peripheral blood flow cytometry suggested T-cell prolymphocytic leukaemia ...

Professor Gordon Cook says careful patient selection is needed with CAR-T cell therapy, noting its potential in a disease ...

Benefit was maintained across MZL subtypes and subgroups, including splenic MZL, with particularly favorable 24-month ...

Bridging therapy was administered to 90% of apheresed patients, with chemotherapy ± radiotherapy used in 53% and targeted ...

Oncology leaders appearing in Atlanta, Georgia, including several from Winship Cancer Institute from Emory University School of Medicine, show how NGS biomarkers and MRD reshape NSCLC and hematology ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

A simple blood test could speed up diagnosis and improve outcomes for children with Africa's most common childhood cancer. In a study published in ...

A new wave of immuno-therapies is reshaping the fight against cancer, turning the body’s own immune system into a powerful ...